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Abstract
The construction and application of biological network models is an approach
that offers a holistic way to understand biological processes involved in
disease. Chronic obstructive pulmonary disease (COPD) is a progressive
inflammatory disease of the airways for which therapeutic options currently are
limited after diagnosis, even in its earliest stage. COPD network models are
important tools to better understand the biological components and processes
underlying initial disease development. With the increasing amounts of
literature that are now available, crowdsourcing approaches offer new forms of
collaboration for researchers to review biological findings, which can be applied
to the construction and verification of complex biological networks. We report
the construction of 50 biological network models relevant to lung biology and
early COPD using an integrative systems biology and collaborative
crowd-verification approach. By combining traditional literature curation with a
data-driven approach that predicts molecular activities from transcriptomics
data, we constructed an initial COPD network model set based on a previously
published non-diseased lung-relevant model set. The crowd was given the
opportunity to enhance and refine the networks on a website (
https://bionet.sbvimprover.com/) and to add mechanistic detail, as well as
critically review existing evidence and evidence added by other users, so as to
enhance the accuracy of the biological representation of the processes
captured in the networks. Finally, scientists and experts in the field discussed
and refined the networks during an in-person jamboree meeting. Here, we
describe examples of the changes made to three of these networks: Neutrophil
Signaling, Macrophage Signaling, and Th1-Th2 Signaling. We describe an
innovative approach to biological network construction that combines literature
and data mining and a crowdsourcing approach to generate a comprehensive
set of COPD-relevant models that can be used to help understand the
mechanisms related to lung pathobiology. Registered users of the website can
freely browse and download the networks.
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REVISED Amendments from Version 1
      
The changes made in the manuscript are as follows:
- We further explained the sentence on page starting “Networks
that were not enhanced with COPD-specific mechanisms from
the literature or RCR included …” by adding : “Although there
may be papers that report on the correlation between COPD and
these processes, network model building requires mechanistic
information that will provide causal links within the model”.
- We have added several references to demonstrate how the
biological signal is interpreted in a meaningful manner using the
causal network models (p. 17).
- When describing the improvements on the Th1-Th2 signaling
network, we have used “more comprehensive” instead of
“comprehensive” (p. 11).
- We have specified in the text (p. 15) that the 886 pieces of
evidence added by the crowd is supported by 479 unique PMIDs.
- We have added a clearer legend for Figure 4 explaining what
the different shaped nodes represent in the networks.
- We have modified Figure 1 and the figure legend explaining the
difference between BEL and OpenBEL (p. 4).
- Figure 2 was slightly modified to better reflect the structure of
the articles in which the networks were originally described. More
specifically, the icon for mucus hypersecretion was moved to
inflammation and response to DNA damage to cell fate.
- We have indicated appropriate references in the discussion
for readers, who wish to find more background information
about the network models and see how they compare with other
approaches to interpret data (p. 16).
See referee reports

Introduction
Molecular networks, such as the KEGG (Kyoto Encyclopedia of
Genes and Genomes) pathways1,2, aid in understanding the complex
interplay of signaling pathways in disease. Biological network models (hereafter referred to as networks) depict the inter-relationships
between multiple signaling pathways and how their perturbations
may dysregulate biological processes, eventually leading to the
disease.
In previously published reports, we described the construction of a
set of 90 networks that captured a large range of biological processes relevant to non-diseased lung tissue3–7. The generation of this
set of networks relied on both manual curation of published literature and a data-driven reverse causal reasoning (RCR) methodology8 to augment the causal biological framework underlying the
network architecture (Figure 1). We used the Biological Expression Language (BEL) to represent precise biological relationships
in a computable and standardized format8. We have built upon this
approach and describe here a unique, three-phase systems biology
and crowdsourcing approach to construct a comprehensive set of
50 molecular networks that describe the biological processes relevant to chronic obstructive pulmonary disease (COPD) and lung
biology (Figure 2). COPD is the fourth leading cause of death
worldwide and its incidence is increasing among chronic diseases
in the USA9,10. COPD is a chronic, progressive inflammatory disease induced by cigarette smoking, inhalation of pollutants, dust,
chemicals, or other foreign matter, which ultimately manifests as

tissue destruction in the alveolar compartments and airflow limitation, leading to reduced oxygen exchange11–15. COPD affects a wide
spectrum of biological processes in lung tissue, such as oxidative
stress, inflammation, apoptosis, proliferation, and senescence16,17.
Understanding the mechanisms involved in these processes is
important in understanding the onset of the disease and in identifying drug targets to develop effective COPD treatments18,19. As
recently reported by the Global Initiative for Chronic Obstructive
Lung Disease (GOLD), current pharmacologic therapies cannot
cure the disease but only reduce the symptoms, and the frequency
and severity of exacerbations, i.e., slow down the rate of disease
progression11; thus it appears most efficient to target the COPDspecific pathomechanisms at the earliest distinguishable state, when
the extent of irreversible damage is still small, and their molecular processes are not yet convoluted with secondary processes and
comorbidities, e.g., bacterial and viral infections, as they occur during the exacerbations typical for later stages of COPD. Since smoking cessation/replacement appears to be the most efficient therapy
in smoking-related COPD11, the models of early onset COPD can
also be expected to be valuable tools for the development and testing of reduced risk products that may prevent COPD progression in
a comparable manner as cessation does.
The networks reported here were created first from a literature scaffold and expanded via data enhancement using RCR (Phase 1), then
they were made available online to the entire scientific community for critical review during the Network Verification Challenge
(NVC) “Open Phase” (Phase 2) under the umbrella of the systems
biology verification (sbv) IMPROVER project20 (Figure 1). Finally,
a prioritized subset of 15 of these networks was discussed during an
in-person jamboree meeting where the crowd-submitted revisions
were reviewed and decisions to improve the networks were finalized (Phase 3). The final versions of the networks are available at
https://bionet.sbvimprover.com for the public to view, and for registered users in the NVC to continue to discuss.
A variety of COPD networks have been created by various research
groups, including networks focused on muscle to study skeletal
muscle abnormalities21, networks to compare COPD and asthma22,
and a knowledge management framework to integrate COPD clinical and experimental data23. To our knowledge, this is the first set
of crowd-verified networks available to the broader scientific community as a unified collection on a freely accessible web-based
platform. Ultimately, this interface will allow for continuous input
and improvement in the networks, leading to better understanding,
diagnosis, and treatment of COPD.

Methods
Results
Data File
2 Datasets
http://dx.doi.org/10.6084/m9.figshare.1284583

Phase 1: COPD enhancements using data and literature
Ninety non-diseased lung networks published previously in the
areas of cell proliferation, cell stress, inflammation, DNA damage,
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Figure 1. Network construction using a systems biology and crowdsourcing approach. Networks were constructed using published
literature and data sets, and opened to the public for comment and editing in the Network Verification Challenge. The three phases of COPD
network construction are shown. (A and B) Phase 1: COPD augmentation using literature and data. (C and D) Phase 2: Online verification by
the public during an “open phase”, and Phase 3: Face-to-face jamboree meeting where scientists and subject matter experts gathered to
discuss the networks and make final decisions for the next versions. *BEL was a proprietary language developed by Selventa. In the interest
of the growing community of researchers using BEL, an openBEL language derived from BEL has been developed and released as open
source. One of the main differences between the two is that in the openBEL, the namespace (i.e. databases in which the biological entity is
defined) is clearly stated, allowing for a better standardization of used ontologies and databases.

cell death, tissue repair, and angiogenesis were used as the initial
scaffolds for COPD enhancement during Phase 13–7. Biological
pathways implicated in COPD disease pathophysiology, including B-cell and T-cell activation, airway remodeling, extracellular
matrix (ECM) degradation, efferocytosis, mucus hypersecretion,
and emphysema were all captured within the modified network
models. In total, 200 new nodes and 487 new edges were added:
415 of the edges were added to incorporate COPD mechanisms
implicated in the literature, and 72 edges were added to incorporate
100 mechanisms predicted from COPD data by RCR to be relevant
to COPD (Figure 3). Because the models were built to represent
COPD in humans, human evidence was preferred and made up the
majority of the networks (74%).
During Phase 1, the networks with the most significant number of
COPD enhancements in terms of percentage of the network with
new nodes were the Mucus Hypersecretion (44%), Th2 Signaling

(37%), Macrophage Activation (28%), Fibrosis (25%), Autophagy
(11%), and Apoptosis (5%) networks. Networks that were not
enhanced with COPD-specific mechanisms from the literature or
RCR included the DNA Damage and Notch Signaling networks.
Although both these networks relevant to the development of
COPD, they were not augmented beyond the original, non-diseased
network scaffolds, because no studies on the differences in signaling
between non-diseased and diseased states were available. Although
there may be papers that report on the correlation between COPD
and these processes, network model building requires mechanistic
information that will provide causal links within the model.
Phase 2: Networks enhanced with lung- and COPD-relevant
mechanisms by the crowd during the open phase
Prior to deploying the COPD-enhanced biological networks on the
NVC website for verification by the scientific community, the set
of 90 networks was agglomerated by the model-building expert
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Figure 2. Fifty networks available during the network verification challenge and their associated biological processes.

team to yield a more concise set of 50 networks that combined
and standardized related/complementary cellular pathways (See
Methods for details). For example, a new “Th1 Signaling” network model was created by merging three of the original networks
that were relevant to the functional biology present in T-helper 1
cell populations: Th1 Differentiation, Th1 Response, and T-cell

Recruitment and Activation. For a list of the original models that
correspond to the agglomerated models and a description of the
new models, see Dataset.
During Phase 2, a global community of scientists participated in
the NVC by contributing their expertise to one or several of the
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network models. Scientists could contribute by verifying existing
evidence for network edges using a system that allowed users to
vote on evidence to indicate agreement or disagreement with its
appropriateness within the network structure and boundary conditions. Participants were also encouraged to add new mechanistic biology in the form of network edges. In total, the 50 network
models received 2456 evidence votes, 1795 of which supported
the confirmation of evidence and 661 that favored the rejection of
evidence (see Dataset). The Neutrophil Signaling network model
received the largest share of voting activity, with 241 total votes
or approximately 10% of all votes cast. Other network models that
received large shares of the votes included the Macrophage Signaling (180 votes) and Th1 and Th2 Signaling network models (105
votes) (see Dataset). In addition to verifying existing literature evidence supporting edges in the network models, NVC participants
could add novel biological information in the form of new literature
evidence (for an existing edge) or contribute new network edges to
incorporate new biological components into the network structure.
In this way, the community of participants collectively contributed
a significant amount of new information into the networks; among
the 50 network models, a total of 885 new pieces of evidence, 351
new nodes, and 451 new edges were added (Figure 3).

in-person jamboree to discuss network refinements as a group.
Additional subject matter experts in the network biology, COPD,
lung biology, and biological processes represented by the networks
were invited to participate in the discussions and contribute their
expert feedback independent from the network-building experts.
Among the 50 network models evaluated during the online NVC,
15 were prioritized and selected for discussion during Phase 3
based on the level of crowd-sourced activity and their importance
in COPD onset as considered by the network-building experts (see
Dataset). The goal of Phase 3 was to provide an additional layer of
“verification” for the online enhancements and to provide holistic
comments on the network models at the molecular/biological entity
level. In doing so, the three network models that had received the
largest amounts of crowd activity (Neutrophil Signaling, Macrophage Signaling, and Th1 Signaling) also underwent significant
additional enhancements to improve granularity with respect to
COPD onset and pathogenesis. In total, 167 nodes and 296 edges
were added among all the network models reviewed during the
jamboree sessions, and the three inflammatory networks received
89% of the nodes and 89% of the edges (148 nodes and 263 edges)
(Figure 3). Many of these changes came from the identification of
missing mechanistic details of processes that occur in COPD (e.g.
chemotaxis mechanisms in the Macrophage Signaling network
model described in the examples in the “Macrophage signaling”
section below).

Phase 3: Jamboree discussion and final decisions for next version
networks
Following Phase 2, a jamboree (Phase 3) was organized for a
group of invited participants to discuss the network enhancements
submitted by the crowd. To represent the crowd community, the
top 20 active performers who created the most pieces of evidence
and submitted at least 20 votes during the NVC were invited to an

Entity

In addition to adding mechanistic details of processes that occur
in COPD, enhancements were incorporated to improve the granularity and connectivity within the network structures. In several instances, the improvements involved the creation of more

Network
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All networks
Macrophage Signaling
Nodes

9
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Figure 3. Nodes and edges added in each phase of COPD network construction. Summary of nodes and edges added to all networks
and to three example networks in each phase. A) Nodes added in each phase. B) Edges added in each phase.
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detailed linear pathways connecting biological components. In one
example, in the Apoptosis network model, the original network
pathway indicated that the X-ray repair complementing defective
repair in Chinese hamster cells 6 (XRCC6) protein decreased the
process of apoptosis24. During the Phase 3 discussions, additional
literature evidence provided a more detailed mechanistic understanding of this phenomenon: XRCC6 was reported to decrease the
activity of the BCL2-associated X protein (BAX) protein, which
is known to increase mitochondrial permeability and therefore
promote apoptosis (Figure 4A). The overall effect of the negative
regulation of BAX by XRCC6 was therefore a decrease in apoptotic cell death25. By improving the granularity of this pathway in
the Apoptosis network, a more comprehensive representation was
achieved for components that are related to critical cellular processes mediating disease onset.
A similar improvement was incorporated into the Mechanisms of
Cellular Senescence network model: the original network pathway
indicated that the chemical acrolein (a common component of cigarette smoke) increased cell senescence26. During Phase 3 discussions, the pathway connecting these two components was expanded
using additional literature evidence. In several studies, acrolein was
found to decrease the activity of sirtuin 1 (SIRT1), which is a known
negative regulator of the forkhead box O3 (FOXO3) transcription

A

factor, and FOXO3 activity is known to promote cellular senescence (Figure 4B)26–28. Therefore, the overall observed effect was
acrolein acting to potentiate cellular senescence in exposed cells,
which is a well-characterized mechanism of action for this toxic
chemical. Again, the generation of more comprehensive network
models of biological processes in close proximity to disease onset
allowed for a greater mechanistic understanding of how environmental factors can contribute to COPD development.

Exemplary outcomes of the three-phase COPD network
building process
Th1 and Th2 signaling
As part of the pulmonary inflammatory process network building6,
five networks (T-cell activation and recruitment, Th1 differentiation,
Th2 differentiation, Th1 Response, Th2 response) were built to
describe Th1 and Th2 signaling in the non-disease lung context.
As described previously, during the preparation phase to NVC, two
networks were built around the Th1 and Th2 cells.
Phase 1: COPD augmentation of T-helper cell networks
Mechanisms that describe T-cell activation and recruitment induced
by neutrophils, macrophages, and dendritic cells were added to
the T-cell networks during Phase 1. These immune cells secrete
various chemokines that were reported to recruit T-cell populations

B
p(HGNC: XRCC6)

bp(MESHPP:Apoptosis)

p(HGNC: XRCC6)

cat(p(HGNC:BAX))

a(CHEBI:acrolein)

path(SDIS:”cell
senescence”

a(CHEBI:acrolein)

p(HGNC: SIRT1)

tport(a(MESHCL:”mitochondrial
permeability transition pore”))

cat(p(HGNC: SIRT1))

bp(MESHPP:Apoptosis)

tscript(p(HGNC: FOXO3))

path(SDIS:”cell
senescence”

Figure 4. Improvements in the granularity of two representative network pathways. Cyan squares represent abundances, triangles
activities, purple squares the movement of abundances from one cellular location to another, and diamonds biological processes. During
Phase 3 of COPD network construction, improvements were made by adding mechanistic details to over-simplistic edges. A) In the Apoptosis
network model, the original connection (left) simply indicated that XRCC6 decreased the process of apoptosis. The improved pathway
connection (right) indicates that XRCC6 decreases the activity of BAX, which normally functions to facilitate the transport of calcium ions
through the mitochondrial pores and thereby increases apoptosis. B) In the Mechanisms of Cellular Senescence network model, the original
connection (left) simply indicated that acrolein increased the process of cellular senescence. The improved pathway connection (right)
indicates acrolein mediates its effects on senescence via the activity of SIRT1 and the FOXO3 transcription factor. Triangle denotes activity,
diamond denotes biological process or pathology, circle denotes abundance, rounded square represents transport, and square denotes
protein abundance nodes. Solid edges denote causal relationships, dotted edges denote non-causal relationships such as a protein
connected to its own activity.
Page 7 of 29

F1000Research 2015, 4:32 Last updated: 14 JUN 2016

(i.e. CD8+ cytotoxic T-cells) to injured tissue in an acute inflammatory state29. Alveolar macrophages secrete interleukin 15 (IL15),
which is capable of activating both the interleukin 2 (IL2) and IL15
receptors on T-cells and acts as a potent inducer of cell migration to
the lung. Dendritic cells within the lung play an important role in
this process by secreting chemokine (C-C motif) ligand 3 (CCL3)
in response to cigarette smoke, which helps recruit CD8+ T-cells
to the lung29. Chemokine (C-C motif) receptor 5 (CCR5) is the
receptor for CCL3 and its presence in the lung has been shown to
correlate with the severity of COPD30. CCL3 is one example of a
node that was added during the literature-based COPD enhancement process in Phase 1 (Figure 5A). Many of the disease-relevant

A

B
p(HGNC: CCL3)

p(HGNC: CCL5)

mechanisms identified in the literature curation phase were corroborated by mechanisms predicted from COPD-relevant data sets
using RCR (see Methods), including T-cell activation mechanisms
(CD28 molecule (CD28) and T cell receptor beta locus (T\RB), and
chemokines and cytokines that activate and are secreted by T-cells
(chemokine (C-C motif) receptor 3 (CCR3), CCR5, IL2, interleukin
4 (IL4), interleukin 6 (IL6), interleukin 10 (IL10) and interleukin
13 (IL13)). The prediction of these mechanisms in COPD data sets
showed that T-cell activation and migration in response to smokeexposed lung represents an important process in the innate immune
response. In total, 30 nodes and 34 edges were added to the Th1
and Th2 networks during the internal COPD enhancement process.

C
p(HGNC: IFNG)

p(HGNC: EGR2)
p(HGNC: IRF2)

cat(p(HGNC:CCR5))

p(HGNC: CBLB)

tscript(p(HGNC:IRF2))

bp(GO:”T cell
activation”)

bp(GO:”T helper 2
cell
differentiation”)

path(SDIS:”T-cell
migration”

D

bp(GO:”memory
T cell
activation”)

p(HGNC: IL5)

tscript(p(HGNC:IRF1))

p(HGNC: IL4)

p(HGNC: CCR5)

p(HGNC: IL25)

p(HGNC: IRF1)

bp(GO:”T helper
type 2 immune
response”)

bp(GO:”T helper
cell
differentiation”)

p(HGNC: IL9)

bp(GO:”T helper
type 2 immune
response”)

p(HGNC: IL10)

p(HGNC: IFNG)

bp(GO:”macrophage
activation”)

Figure 5. Enhancement of the T-cell networks during COPD network construction. A) During the literature-based COPD enhancement
process in Phase 1, the protein CCL3, important for leukocyte migration and activation of T-cells, was added to the T-cell networks.
B) During the open phase in Phase 2, the negative regulation of EGR2 on T-cell activation is a mechanistic detail that was added by the
crowd. Overexpression studies demonstrated that EGR2 increased the activity of the E3 ubiquitin ligase CBL-B, which subsequently inhibited
T-cell activation. C) During the jamboree discussions in Phase 3, the IFNG/IL-4 feedback loop mediating differentiation of Th1 vs. Th2 cellular
subtypes via the activities of IRF1 and IRF2 was added to the new Th1-2 Signaling network model. D) During the jamboree discussions in
Phase 3, the T-helper cell-produced chemokine effect on immune cells (e.g. IL-25 activates memory T-cells) was added to the new Th1-2
Signaling network. Triangle denotes activity, diamond denotes biological process or pathology, and square denotes protein abundance nodes.
Solid edges denote causal relationships, dotted edges denote non-causal relationships such as a protein connected to its own activity.
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Phases 2 and 3: T-cell network crowd improvements
During the open phase (Phase 2), the Th1 and Th2 networks
received 105 votes from the scientific community, as well as 10
new nodes, 9 new edges, and 13 new pieces of evidence. One such
addition to the Th1 Signaling network was the regulatory influence
of early growth response 2 (EGR2) on T-cell activation; the submitted evidence demonstrated that overexpression of EGR2 promoted
increased activity of the E3 ubiquitin ligase CBL-B and subsequent
inhibition of T-cell activation31 (Figure 5B).
During the Phase 3 jamboree sessions, the group decided to combine the individual Th1 Signaling and Th2 Signaling networks into
a single, unified network model titled Th1-Th2 Signaling to better represent the interplay between the T-helper cell populations
in vivo. It was also decided to add granularity to transcriptional
pathways mediating Th1 versus Th2 cellular activation and differentiation; one example was the addition of two transcription factors, interferon regulatory factors 1 and 2 (IRF1 and IRF2), that are
known to act downstream of interferon-gamma (IFNG) to suppress
IL4 expression in Th2 cell populations32. IFNG is secreted by Th1
cells and this pathway potentiates Th1 responses while suppressing
Th2 responses in the tissue. The addition of this feedback mechanism during Phase 3 contributed to a more comprehensive network
describing the interactions between Th1 and Th2 cells (Figure 5C).
Further network enhancements discussed in the jamboree largely
emphasized the downstream effects of T-helper cells in potentiating
inflammatory signaling by activating additional immune cells in a
disease context. For example, secretion of IL5 activates eosinophils,
whereas secretion of IL10 and IFNG activates macrophages in the
diseased tissue33–35. This interplay between immune cell populations was incorporated into the new Th1-Th2 Signaling network
model and better captures the signaling interconnectivity present
during disease development (Figure 5D). In total, 12 new nodes
and 28 new edges were added to the Th1-Th2 Signaling network
model during the jamboree discussions, thereby creating a more
comprehensive biological network of T-helper cell activity and
their interactions with other immune cells in the context of COPD.

Macrophage signaling
As part of the pulmonary inflammatory process network building6,
three networks (Macrophage Differentiation, Macrophage Activation, and Macrophage-mediated Recruitment of Neutrophils) were
built to describe macrophage biology in the non-disease lung context. During the preparation phase to NVC, these three networks
were merged to obtain an overall picture of macrophage biology.
Phase 1: COPD augmentation of macrophage networks
Macrophages play roles in many COPD disease processes such as
clearance of apoptotic neutrophils, tissue destruction, and recruitment
of other immune cells by their secretion of cytokines36. Macrophage signaling mechanisms were added to the network in Phase 1,
with a focus on components related to efferocytosis (Figure 6A).
Efferocytosis is a well-conserved mechanism for the phagocytic
removal of apoptotic cells by innate immune cells, such as macrophages, and the process is critical for the resolution of inflammation via the removal of dying cells and antigenic cellular debris.
Phagocytically impaired macrophages have been shown to display decreased expression of peroxisome proliferator-activated

receptor gamma (PPARy) and efferocytosis-specific bridge molecules, such as growth arrest-specific 6 (GAS6) and milk fat globule-EGF factor 8 protein (MFGE8)37. The number of apoptotic cells
was shown to increase in COPD because of exposure of lung tissue
to toxic chemicals present in cigarette smoke; for example, and their
accumulation was exacerbated by the simultaneous smoke-induced
impairment of the phagocytic ability of alveolar macrophages38.
Apoptotic cells exhibit surface changes that distinguish them from
viable cells, and these changes were recognized by efferocytic
receptors including CD36 molecule (CD36), CD14 molecule
(CD14), and Stabilin-1/2 (STAB1:STAB2)39. Reduced efferocytosis observed in COPD because of oxidant-driven and Rho-mediated
inactivation increased the likelihood of aberrant antigen exposure
from apoptotic cells, thereby perpetuating the chronic inflammatory state that is a hallmark of COPD40–42. In adding efferocytosis
mechanisms to the macrophage network, we focused on the surface
receptors and bridge proteins such as CD36 and GAS6. In total, 45
nodes and 61 new edges were added to the macrophage model during the internal COPD enhancement phase.
Phases 2 and 3: Macrophage network crowd improvements
During the open phase (Phase 2), 180 total votes were cast for network evidence, with 23 new nodes and 39 new edges added by the
crowd. In addition, 72 new pieces of evidence were contributed to
support pre-existing edges in the network. The surfactant protein
A1 (SFTPA1), which was observed to be increased in COPD43, was
added to the network. Its effect on macrophages of increasing interleukin-1 receptor-associated kinase 3 (IRAK3) and interleukin 1,
beta (IL1B) were also added to the network during the open phase.
Granularity enhancements around IFNG and nucleotide-binding
oligomerization domain containing 2 (NOD2), both components of
inflammatory signaling, were also added to augment the network
models with causal relationships proximal to COPD.
During the Phase 3 jamboree discussions, several network enhancements were made in macrophage chemotaxis and differentiation
(Figure 6B). Within the chemotaxis process, the nodes chemokine
(C-C motif) ligand 2 (CCL2) binding to chemokine (C-C motif)
receptor 2 (CCR2) and leading to macrophage chemotaxis were
added. The CD69 molecule (CD69) associated with macrophage activation by cigarette smoke was also added. In addition,
the effects of activated macrophages on other immune cells were
expanded within the network model, including chemokine (C-X-C
motif) ligand 1 (CXCL1) and chemokine (C-X-C motif) ligand 2
(CXCL2) leading to neutrophil chemotaxis, and chemokine (C-X-C
motif) ligand 9 (CXCL9) and chemokine (C-X-C motif) ligand 10
(CXCL10) binding to CXCR3 and leading to T cell recruitment. In
total, 30 new nodes and 48 new edges were added to the Macrophage Signaling network during Phase 3, thereby providing a more
comprehensive network of macrophage activation and its effect on
other immune cells active in COPD.

Neutrophil signaling
As part of the pulmonary inflammatory process network building6,
two networks (Neutrophil Response and Neutrophil Chemotaxis)
were built to describe neutrophil biology in the non-disease lung
context. During the preparation phase to NVC, these two networks
were merged to constitute the Neutrophil Signaling network.
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Figure 6. Enhancement of the macrophage networks during COPD network construction. A) During the literature-based COPD
enhancement process in Phase 1, efferocytosis mechanisms were added to the macrophage networks to take into account its dysregulation
effect in COPD. B) During the jamboree discussions in Phase 3, chemotaxis and differentiation mechanisms were identified and subsequently
added to the latest version of the Macrophage Signaling network. Triangle denotes activity, diamond denotes biological process, and square
denotes protein abundance nodes. Solid edges denote causal relationships, dotted edges denote non-causal relationships such as a protein
connected to its own activity.
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Phase 1: COPD augmentation of neutrophil networks
During Phase 1, the Neutrophil Signaling network was enhanced
primarily with components related to lipid-response pathways. In
response to lung damage, leukocytes and tissue-resident cells were
reported to interact to generate lipid mediators that enhance the
airway immune response and engage defense mechanisms44. Neutrophils, endothelial cells, and macrophages generate prostaglandins
and leukotrienes from arachidonic acid during the initial inflammatory response, which amplifies the inflammation signals in the
local area and potentiates the process of tissue destruction45. Subsequently, the prostaglandins PGE2 and PGD2 are generated in a
cyclooxygenase-dependent way to promote synthesis of lipid mediators with anti-inflammatory activity, such as the lipoxins. Lipoxins
inhibit neutrophil recruitment to inflamed sites and suppress their
pro-inflammatory actions, but promote recruitment of macrophage
precursors46. Lipoxin A4 stimulates macrophages to phagocytose
apoptotic neutrophils, and resolvins and protectins, which represent

another class of lipid mediators, activate anti-inflammatory pathways and stimulate clearance of inflammatory infiltrates by macrophage phagocytosis47–49. In total, 9 nodes and 20 edges were added
to the network model including lipid mediators such as lipoxin A4,
resolvin E1, and neuroprotectin D1 (Figure 7A).
Phases 2 and 3: Neutrophil network crowd improvements
The Neutrophil Signaling network was the network most edited
by the crowd during the open phase, with the addition of 116 new
nodes, 160 new edges, 181 new pieces of evidence, and 241 votes
cast. The new edges described neutrophil chemotaxis including new
nodes like platelet factor 4 (PF4) and protease-activated receptor
2 (F2RL1). Chemokines such as chemokine (C-X-C motif) ligand
8 (CXCL8) and chemokine (C-X-C motif) ligand 12 (CXCL12),
and members of the serine/threonine kinase (AKT) family that have
also been shown to induce neutrophil chemotaxis were added to the
network (Figure 7B)50.
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Figure 7. Enhancement of the neutrophil network during COPD network construction. A) During the literature-based COPD enhancement
process in Phase 1, lipids and their effects on neutrophil chemotaxis were added to the new Neutrophil Signaling network. B) During Phases
2 and 3, neutrophil adhesion and chemotaxis mechanisms were added to the new Neutrophil Signaling network. Triangle denotes activity,
diamond denotes biological process, circle denotes abundance, and square denotes protein abundance nodes. Solid edges denote causal
relationships, dotted edges denote non-causal relationships such as a protein connected to its own activity.
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Following the jamboree discussions, additional signaling that
described cytoskeletal and adhesion mechanisms necessary for
neutrophil chemotaxis, and additional neutrophil activation mechanisms, were incorporated in the new Neutrophil Signaling network
(Figure 7B). The role of the CDC42-WASp complex in regulating
neutrophil chemotaxis at the cytoskeletal level was incorporated51,
as well as other mechanisms of neutrophil chemotaxis including the role of the complement component 5 (C5) in regulating
integrin, alpha M (ITGAM)52, and the role of CCL3/CCR5 in
stimulating neutrophil migration53. In all, 69 nodes and 129 edges
were added. The new mechanisms that were incorporated into the
Neutrophil Signaling network added significant granularity to the
neutrophil chemotaxis process, which is a key driver of the inflammatory cascade that promotes the development of COPD.

Discussion
Here we report the construction of a COPD-enhanced network
model set using a novel methodology that combined traditional
manual literature curation and data-driven approaches with a global
crowdsourcing endeavor to generate the most comprehensive representation of biological phenomenon proximal to the onset of COPD
that is available to date. The three phases of network construction
each contributed in different ways to building a more comprehensive network. The Phase 1 literature and data-driven enhancement of the already existing non-diseased networks resulted in the
addition of COPD biomarkers and disease drivers known to be
associated with COPD, while the Phase 2 crowdsourcing largely
focused on contributions to cell-specific networks, and the Phase 3
jamboree discussions uncovered missing signaling processes relevant to COPD.

COPD biomarkers and processes added to non-diseased
networks
During Phase 1, the non-diseased networks were expanded within
the COPD context by the addition of biomarkers, disease drivers,
and processes that were reported to increase in COPD, as well as
mechanisms predicted in COPD data sets. Most of the edges added
to the networks were lung relevant but not specifically investigated
in a COPD background. Because of the limited number of mechanistic studies in COPD models that have been published, network
construction was focused on adding COPD-known processes and
biomarkers in tissue and experimental contexts relevant for COPD
(lung, smoking) to the existing non-disease networks.
Modeling the process of efferocytosis is an example of the addition
of COPD processes to the non-disease networks. The efferocytosis
process of phagocytic uptake of apoptotic cells by macrophages is
frequently disrupted in COPD tissue, and this disruption is thought to
potentiate the chronic state of inflammation in the diseased lung40–42.
A new network model detailing components related to efferocytosis was constructed from information available in the published
literature with the majority of edges coming from general macrophage experiments. Th2 activation cascades and macrophage signaling events were also implicated generally in the context of COPD,
and therefore the non-diseased network models were enhanced by
the addition of these pathways from lung-relevant studies. Network models detailing other processes not widely implicated in
COPD, such as DNA damage and Notch signaling, which are more

generalized conserved biological phenomenon, received very few,
if any, enhancements during the COPD literature curation phase.
In addition to adding COPD processes during Phase 1, we also added
COPD biomarkers and mechanisms predicted by RCR to be active in
COPD data sets. Biomarkers associated with COPD included chemokines, cytokines, matrix metalloproteinases (MMPs), and other
matrix degradation products. Examples of cellular mechanisms
uncovered by the data-driven approach included the cytokines IL19
and IL3, as well as the serine protease inhibitor SERPINA1. IL3 is a
growth-stimulating cytokine for many inflammatory cells, including
macrophages, and IL19 is produced by monocytes and activates the
inflammatory STAT3 pathway in several cell types. SERPINA1 is a
potent elastase inhibitor, the presence of which plays a critical role
in controlling the protease cascade leading to tissue destruction and
emphysema. Overall, the RCR approach yielded a diverse range of
biological features that were incorporated among a large percentage
of the network models, thereby broadening the scope of many networks to include components with potential connections to disease
that have not been investigated previously in the COPD context.

Crowdsourcing efforts focused on cell-specific networks
During the NVC, scientists from around the world browsed the
publically available networks on a website, voted on and submitted
new evidence, and created new nodes and edges. As may have been
expected, several of the more well-studied processes in the literature
(e.g. NF-kB pathways leading to inflammatory signaling) attracted
a great deal of voting activity within the networks and primarily
corroborated known biology. However, participants were incentivized to create new evidence to support existing edges based on the
large number of points received by them for this activity. It was this
aspect of the challenge that truly demonstrated the power of crowdsourcing because, in many instances, the community of users located
lung-relevant and/or more recent publications to better support the
existing network architecture and improve the overall relevance of
the network models to COPD. With nearly 900 new pieces of evidence (from 479 unique PMIDs) added by the challenge crowd, a
significant overall enhancement of the networks was achieved in a
relatively short time (5 months), which demonstrated the remarkable utility of harnessing knowledge from the global scientific community for a specific application. Specifically, 30% (266/885) of all
the new pieces of evidence and 46% (208/451) of all the new edges
that were contributed fell within three network models, namely the
Neutrophil Signaling, Macrophage Signaling, and Th1-Th2 Signaling networks. These networks were edited more than other networks
because of their clear boundaries, which allowed scientists to narrow
their search to a particular cell type. Networks such as Clock, Wnt,
mTor, and Regulation of CDKN2A expression were edited minimally
and received more ‘Down’ votes than the cell-specific networks,
possibly because of the more ambiguous boundaries of which cell
types could be included. This observation emphasizes the need
for clear boundaries in a crowdsourcing effort. In the case of general networks such as Cell Cycle, Response to DNA Damage, and
Oxidative Stress, many experiments concerning these processes
have been performed in cell types that were excluded in our boundaries (i.e. tumorigenic cell lines). Perhaps boundary conditions
could be loosened for networks such as these if it is assumed that
signaling is conserved across different cell types.
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Jamboree discussions identified missing processes
relevant to COPD
The final phase of network improvements emphasized the discussion
and consolidation of all submissions from the challenge crowd to
synthesize more holistic changes within the set of network models.
During the challenge, participants worked individually on the website adding individual edges, but did not have the ability to make
major changes to the structure of the network models. The in-person
jamboree discussions were therefore an opportunity to implement
broader changes to better represent the biological processes as they
related to COPD. These discussions were led by experts in the subject matter of the processes that the networks represented. During
these sessions, missing pieces of biology and the interactions of
different cell types in COPD were identified. In this manner, the
jamboree was very conducive to broader network structural changes
that made the set of network models more informative and representative of processes implicated in COPD and, therefore, more
useful to a broader group of scientists.
Unique features of the collaborative networks
In recent years, crowdsourcing has emerged as a powerful tool to
address topics related to “big data” in the domain of the life sciences, particularly in topics related to systems biology. For example,
the series of DREAM challenges empowered the global scientific
community to build application-specific, clinically relevant predictive biological networks using vast quantities of genomic data54.
Similarly, the recent sbv IMPROVER challenges allowed researchers to participate in collaborative competitions to validate systems
biology research, for example, by testing and validating computational approaches that are used to classify clinical samples based
on transcriptional data55–57. In the current approach, we describe a
unique paradigm for biological network construction that combines
a predictive computational methodology with a large-scale crowd
sourcing approach to generate very comprehensive network models
describing COPD pathogenesis.
Compared with other published COPD networks, the networks
described here are more comprehensive in scope, are focused on
molecular pathways that can drive disease rather than on descriptions of more general clinical or physiological measures, and have
been improved using crowdsourcing21–23. The Synergy-COPD
European project is similar in its goal of creating a model of COPD
for better understanding of the disease by combining information
from many different sources. However, Synergy-COPD comprises
seven physiological-focused mathematical networks rather than the
50 molecular networks described here, and does not currently have
an intuitive web interface that allows users to freely navigate the
resulting networks23.
Compared with other more general pathway approaches such as
KEGG1, the networks we describe contain edges that have one or
more detailed evidences supported by a specific literature reference
and contain tissue and species-level metadata. In our approach each
of these pieces of evidence under an edge can be validated with
the potential for a larger crowd with wide expertise, compared to
a non-crowdsourced approach where the small group constructing
the networks may not be able to sufficiently cover all the expertise
necessary to verify every pathway within these networks. The BEL

language syntax allows many participants to contribute by standardizing the biological representation and requiring that each node
be associated with a namespace, which standardizes the representation of gene names and biological processes. The comparison of our
network models with other resources has been described in other
articles58,59 and in a book chapter60.
The web-based platform captures network provenance, allowing for a transparent record of what has been validated with a full
revision history58. The uncertainty for specific edges based on
voting patterns can be demonstrated with the full voting history
being captured in the network versions. By incorporating a continuous “feed” of real time enhancements submitted on the website, users are able to view the most up-to-date networks at any
time; network models created using other platforms not available
for crowdsourced editing remain static representations of biology
and frequently do not include the most recent findings from the
scientific literature. Currently networks with the most recent crowd
edits can be viewed, but not downloaded. Networks with changes
from the most recent Jamboree meeting are made available for
download.
Another novel component of these networks is the incorporation of
RCR predictions to enhance the overall biological representation
within the network models. RCR analysis was performed on human
COPD gene expression data sets in the public domain in order
to predict potential mechanisms implicated in COPD onset and
include as nodes in the networks. This unbiased approach resulted
in the addition of many new nodes among the networks predicted to
be active based on COPD gene expression footprints that may have
less well-established or direct connections to disease etiology. As
such, this important aspect of network construction potentially captures those biological components that may have “emerging” roles
in disease progression. The iterative nature of the network enhancement process facilitated by the Bionet platform allows for new biology and supporting evidence to be incorporated into the networks
as new findings emerge in the literature and therefore generate the
most comprehensive, up-to-date COPD model sets available to the
scientific community.
The utility of the resulting networks and to further analyze the
crowdsourcing process itself can be assessed by evaluating the
impact of the changes on the analyses we have published previously60–67. Moreover, an extensive analysis leveraging multiple relevant datasets will be conducted and the results will be published.
The enhanced crowd-verified models are publicly available on the
sbv IMPROVER website (https://bionet.sbvimprover.com/) and
remain open to receive further enhancements from the online community. Because the first iteration of the NVC proved the effectiveness of this approach and because the networks can continue to be
reviewed by the crowd, a second iteration of the NVC (NVC2) has
been started so that additional modifications and recently published
literature can be incorporated. This will help to continually refine
the network models and strengthen the relevance to the processes
that underlie the development of COPD. The crowd verification
approach continues to be refined, so, in addition to disease processcentered networks, other networks including chemical-centered
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networks can be built using a similar approach. These networks can
aid in the development of more efficient interventions and enhance
toxicological assessment of environmental exposures that may also
contribute to the development of COPD.

Conclusion
Here we describe a novel approach to biological network construction and have generated a suite of COPD-relevant network models
that the larger scientific community is free to edit and explore. Networks are available for download from the sbv IMPROVER website (https://bionet.sbvimprover.com/) upon registration and taking
a certain number of actions as a participant (e.g., voting on an evidence). Scientists from all backgrounds are encouraged to submit
additional network enhancements as participants in the NVC268. By
building the network model set in the BEL language format, we
have generated a model framework suitable for biomarker discovery and for the interpretation of transcriptomic signatures59–66. More
generally, this large assembly of biological knowledge relevant
to human lung will be of great use to both academic and industry
users in promoting future research in this area of great therapeutic
importance.

Methods
Phase 1: COPD enhancement using data sets and literature
Networks that described molecular mechanisms of five broad biological processes were constructed previously using a literature
and data mining approach. These networks cover mechanisms
of cell proliferation5, cell stress4, DNA damage, autophagy, cell
death and senescence3, pulmonary inflammation6, and tissue repair
and angiogenesis7 in the non-diseased pulmonary context. To create COPD-relevant networks, these non-diseased networks were
enhanced by incorporating COPD mechanisms sourced using a literature and data set approach (Figure 1) in an iterative approach, as
described in detail for the non-diseased network model construction, by a team of subject matter experts in computational biology,
molecular biology, inhalation toxicology, and COPD.

Boundary conditions
Because the goal of the research was to understand COPD onset,
the focus of these networks was on early stage COPD mechanisms
(Global Initiative for Chronic Obstructive Lung Disease (GOLD)
stages I and II). When supporting literature from early COPD studies was not available, stage-independent COPD studies were used.
When COPD studies were not found, the inclusion criteria were
expanded to studies from non-diseased context, and mechanisms
active in processes implicated in COPD were incorporated into the
disease models. Literature describing the processes active in acute
exacerbation in COPD patients was excluded from the supporting
edges of the network models. In order to focus on the molecular
mechanisms most specific to early stage COPD, we also excluded
context from diseases with different pathogenesis and differential
diagnosis: lung cancer and non-cancerous lung diseases, such as
cystic fibrosis, acute respiratory distress syndrome, idiopathic
pulmonary fibrosis, septic pneumonitis, obliterative bronchiolitis,
pneumoconiosis, bronchiectasis, viral and bacterial infections, and,
allergic responses/asthma, bronchitis. Animal inhalation studies
with solid particles (e.g. titanium dioxide, quartz, asbestos, carbon
black, and diesel exhaust) were also excluded due to their specific

mode of action. Ideally, all nodes and edges of the network model
would be supported by published data from experiments conducted
in the tissues and cell types found in the lung under the conditions
of early COPD, e.g., airway and alveolar epithelial cells, lung
fibroblasts, resident and recruited immune cells, and microvascular
cells. These were prioritized but the respective cell types were also
considered from other tissue origin if such lung specific context
was not reported in the literature. For in vitro-specific exclusion
criteria, tumor-derived cell lines, immortalized cell lines, neuronal
cells, and cell types that are not found in the respiratory/vascular
system were excluded. In some cases, we made exceptions and
included non-lung cell types for canonical mechanisms for which
there was additional evidence from the literature that the relationship was not tissue-specific but could also take place in the lung.
Human-specific connections were prioritized, but where human data
were not available, knowledge has been augmented with orthologous causal assertions derived from rat and mouse sources included
after homologization in the Selventa knowledgebase where human
data were not available5.
The 90 previously published non-diseased network models used for
the initial substrate included networks involved in cell proliferation5, cell stress4, DNA damage, apoptosis, senescence, autophagy,
necroptosis (DACS)3, pulmonary inflammation (IPN)6, and tissue
repair and angiogenesis (TRAG)7. The Endothelial Shear Stress
network from the cell stress model was excluded because the focus
of the COPD Network was to describe lung biology.

Literature enhancement
We conducted a broad survey of the literature to locate studies that
had investigated the mechanistic biology of COPD pathogenesis
and processes involved in COPD. Potential COPD biomarkers from
sputum, bronchoalveolar lavage, and mouse and human blood samples, and mechanisms that regulate COPD processes were gathered
from the literature and curated. Because only a small number of the
studies had focused on early COPD, we expanded our searches to
include stage-independent COPD studies, but excluded late-stage
processes. Some processes known to be closely linked to COPD
pathogenesis (e.g. B-cell activation and T-cell recruitment to lung
tissue) have not been studied directly in the disease context; however, literature that detailed cell-type-specific canonical biology
was sourced irrespective of the disease context.
Data enhancement
RCR was performed using Gene Expression Omnibus (GEO)
COPD and emphysema data sets from lung, small airway, and alveolar macrophages of early COPD patients and healthy smokers (see
Dataset)69–73. RCR has been used previously to predict upstream
regulators from transcriptomic data8. Mechanisms that were predicted by RCR to be active and that were not already incorporated
in the non-diseased networks were vetted on an individual basis to
locate supporting literature for their potential involvement in COPD
pathogenesis. Mechanisms that had not been studied directly in a
COPD context were evaluated in an expanded tissue context to consider tissue deemed disease-relevant (e.g. alveolar macrophages).
Mechanisms that were deemed relevant were connected in the most
appropriate network based on their probable roles in COPD or lung
biology.
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Network agglomeration
To generate a more concise model set for presentation to the crowd
during the NVC, we consolidated networks associated with related
biological processes among the 90 COPD-enhanced networks. An
example of this consolidation is the merging of three non-disease networks related to T-helper 1 cells (Th1 Differentiation, Th1 Response,
and T-cell Recruitment/Activation) into a single new Th1 Signaling network. Fifty-six of the original 90 networks were combined
into a concise set of 16 network models; the remaining 34 networks
remained as standalone network models (see Dataset), yielding
a final set of 50 models that were posted on the NVC website for
review by the scientific crowd. In addition to the network agglomeration, protein, gene expression, and secretion edges were agglomerated to reduce the number of edges required for verification.
Phase 2: NVC Open Phase
The crowd verification process of improving biological networks
has been published previously20. Briefly, the full set of 50 COPDrelevant network models was posted on the BioNet web portal68
for a period of 20 weeks (the “Open Phase”), during which time a
global community of participants were invited to submit biological
improvements to the models. The improvements included submission of new evidence, additional literature publications to support
existing network edges, and submission of new biological edges
with supporting evidence for relationships that were not represented in a network. Users could also vote on evidence to indicate
agreement or disagreement with its appropriateness within the network structure; disagreements often indicated improper tissue or
experimental context for the given network. Evidence that received
at least four ‘Up’ votes was “locked” to indicate crowd approval
and evidence that received at least four ‘Down’ votes was “locked”
to indicate rejection by the crowd. Depending on the frequency and
type of submitted improvements, participants received credit points
and were assigned a dynamic ranking on the community Leaderboard. For more information about the NVC challenge, see the
5-minute overview videos at https://sbvimprover.com/challenge3/videos or the 1-hour webinars at https://sbvimprover.com/challenge-3/tutorials.

Phase 3: Jamboree meeting
When the open phase was closed, the top-ranked participants were
invited to a 3-day-long in-person jamboree to discuss improvements
submitted by the community and to further refine the network models. Subject matter experts in lung, COPD, and network biology,
as well as experts in other related biological processes, were also
invited to guide the discussions and to provide expert feedback of
missing or misrepresented signaling. Scientists involved in the construction of the original non-disease networks and Phase 1-enhanced
networks were present to provide feedback for the rationale behind
the boundary conditions and the mechanics of network construction and BEL. During the jamboree, 15 networks were prioritized to
discuss in small groups of 6–10 people focusing on one network at
a time. At the end of each session, final decisions were made about
follow-up actions for each network and these actions were carried
out subsequently by the scientists who constructed the original networks because of their familiarity with the mechanics of network
construction and BEL.
The changes to the 15 networks that were discussed during the
jamboree are posted online68 in open-source XGMML (eXtensible
Graph Markup and Modeling Language) format.

BEL: the language of the networks
The networks were built using the Biological Expression Language (BEL), which is an open source language that can represent
scientific findings in the life sciences in a computable form74.
BEL was designed to represent scientific findings by capturing
causal and correlative relationships in context, where context can
include information about the biological and experimental system
in which the relationships were observed and the supporting publication citations. The structure of a BEL node, which includes
the biological entity, the namespace or database to standardize the
nomenclature of the entity, and the function that describes the type
of entity (protein, chemical, biological process, family, complex,
etc), is shown in Figure 8. Table 1 and Table 2 show the definition
of the prefixes for BEL namespaces and functions that appear in
the networks.

En�ty

Biological entity of interest,
e.g. gene, protein, chemical,
biological process

p(HGNC:AKT1)
BEL Func�on
Describes the specific form of
the entity, e.g.:
p: protein abundance
a: abundance
bp: biological process
kin: kinase activity

Namespace
Represents a public database containing the
Entity to enable a standard nomenclature,
e.g.:
HGNC, MGI, EGID, CHEBI, GO

Figure 8. Structure of a BEL node. A BEL term is the standard way a node is described. It includes an entity that is described using standard
nomenclature in the Namespace and the Function fields of the entity.
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Table 1. BEL functions.

Table 2. BEL namespaces.

Prefix

Function

Prefix

Namespace

a

abundance

EGID

Entrez Gene Identifiers

bp

biological process

HGNC

HGNC Approved Gene Symbols

cat

catalytic activity

MGI

MGI Approved Gene Symbols

sec

cell secretion

RGD

RGD Approved Gene Symbols

SPAC

Swiss-Prot Proteins (Accession Numbers)

surf

cell surface expression

SP

Swiss-Prot (Entry Names)

chaperone activity

HGU95AV2

Affymetrix GeneChip Human Genome U95Av2

HGU133AB

Affymetrix GeneChip Human Genome U133AB

HGU133P2

Affymetrix GeneChip Human Genome U133Plus2

MGU74ABC

Affymetrix GeneChip Mouse Genome U74ABC

MG430AB

Affymetrix GeneChip Mouse Expression Set 430

chap
complex

complex abundance

composite

composite abundance

deg

degradation

fus

fusion

MG4302

Affymetrix GeneChip Mouse Genome 430 2.0

g

gene abundance

MG430A2

Affymetrix GeneChip Mouse Genome 430A 2.0

RG230AB

Affymetrix GeneChip Rat Expression Set 230AB

RG2302

Affymetrix GeneChip Rat Genome 230 2.0

gtp

GTP bound activity

kin

kinase activity

CHEBIID

Chemicals of Biological Interest (Identifiers)

m

microRNA abundance

CHEBI

Chemicals of Biological Interest (Names)

act

molecular activity

LMSD*

LIPID MAPS Structure Database (Names)

path

pathology

GOAC

GO Biological Processes (Accession Numbers)

pep

peptidase activity

GO

GO Biological Processes (Names)

MESHPP

MeSH Phenomena and Processes (Names)

phos

phosphatase activity

MESHD

MeSH Diseases (Names)

p

protein abundance

MESHCL

MeSH Cell Locations (Names)

pmod

protein modification

GOCCACC

GO Cellular Component (Accession Numbers)

rxn

reaction

GOCCTERM

GO Cellular Component (Terms)

ribo

ribosylation activity

PFH

Named Human Protein Families

NCH

Named Human Complexes

r

RNA abundance

PFM

Named Mouse Protein Families

sub

substitution

NCM

Named Mouse Complexes

tscript

transcriptional activity

PFR

Named Rat Protein Families

NCR

Named Rat Complexes

SCHEM

Selventa Legacy Chemical Names

SDIS

Selventa Legacy Disease Names

tloc

translocation

tport

transport activity

trunc

truncation

Data availability
Up-to-date networks including all users’ activity can be browsed
freely on the Bionet website (https://bionet.sbvimprover.com/).
Permanent URLs to each network are listed in the associated Data
Set (Original networks, NVC networks and their descriptions). Networks can be downloaded by logged in users who had a few actions
on the site as XGMML file for offline use in the version that started
a verification phase, i.e. after review and QC by experts. The 15
networks discussed in the jamboree are available in a post-jamboree

*Unofficial BEL namespace to be formalized in BEL 2.0

version. Moreover, different versions of the networks are available
to browse and download in diverse formats from the CBN database
available at causalbionet.com.

Data availability
Figshare: Original networks, NVC networks and COPD data
sets used in: Enhancement of COPD biological networks using a
web-based collaboration interface http://dx.doi.org/10.6084/m9.
figshare.128458375
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1-5]. Based on relevant reviews in the area and context of interest, research papers that report the
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High quality curation by trained database curators is needed in our community to convert the literature to
computable models, but it is difficult to imagine how manual curation will scale to handle the ever-growing
data generation rate in biology. Thus, the biological research community needs to figure out how to get
crowdsourcing working for everyone as a tool to improve access to computable data. This paper does a
very good job of describing how a set of COPD networks were constructed and enhanced (they grew in
size and level of detail) through an interesting three-phase process. However, it would be useful to better
describe the utility of the resulting networks and to further analyze the crowdsourcing process itself.
Addressing these points will give the work a broader impact.
Utility of networks:
It is not clear what advantages the use of causal networks brings compared to more established models
in the community, such as molecular interaction networks used by many algorithms (e.g. gene function
prediction, module detection, interpretation of molecular profile data, network biomarkers) or detailed
biochemical pathway models (used by most textbooks and pathway databases). While many results are
published in terms of causal networks (e.g. A activates B), one important issue with networks constructed
by collecting these relationships is that they may be difficult to integrate across resources since they are
context specific: A may activate B in the lung, but inhibit B in the heart and when these are integrated, a
conflict arises. Many computational analysis methods require integration of networks from multiple
sources to construct the largest available network and integrate this data with disease-specific molecular
profile data (e.g. gene expression data) to gain context (as it seems is done in the RCR approach). It
would be useful for the authors to further discuss the utility of context-specific causal networks for follow
on discovery.
I only noticed one sentence mentioning use: “By building the network model set in the BEL language
format, we have generated a model framework suitable for biomarker discovery and for the interpretation
of transcriptomic signatures found in human lung tissue.” However, this sentence is not clear and doesn’t
cite any prior literature. How does using the BEL format create models suitable for biomarker discovery?
Can’t molecular interaction or other types of networks also be used for biomarker discovery? What type of
biomarker discovery is referred to here? How are transcriptomic signatures interpreted and analyzed?
Crowdsourcing comments:
“Networks that were not enhanced with COPD-specific mechanisms from the literature or RCR included
the DNA Damage and Notch Signaling networks. Although both these networks relevant to the
development of COPD, they were not augmented beyond the original, non-diseased network scaffolds,
because no studies on the differences in signaling between non-diseased and diseased states were
available.” How do the authors know that no relevant studies were available? It seems that many papers
at least have discussed links between COPD and DNA damage or Notch signaling (e.g. PMID: 19106307
published in 2009 “Down-regulation of the notch pathway in human airway epithelium in association with
smoking and chronic obstructive pulmonary disease.”)
“In total, 12 new nodes and 28 new edges were added to the Th1-Th2 Signaling network model during the
jamboree discussions, thereby creating a comprehensive biological network of T-helper cell activity and
their interactions with other immune cells in the context of COPD.” How is ‘comprehensive’ measured?
How do we know how much of the available literature was covered by the crowdsource process? That is,
what is the sensitivity of the crowdsourcing process?
How many contributors were involved in enhancing each network in phase 2? Where were they from e.g.
academia, industry? What incentivized them to contribute – for instance, were they COPD researchers?
For the sake of research into crowdsourcing in biology, it would be very useful to provide additional
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academia, industry? What incentivized them to contribute – for instance, were they COPD researchers?
For the sake of research into crowdsourcing in biology, it would be very useful to provide additional
analysis of the contributor community. We need to learn more about what works and what doesn’t in
crowdsourcing initiatives so future generations of these approaches can be improved.
The authors state “With nearly 900 new pieces of evidence added by the challenge crowd, a significant
overall enhancement of the networks was achieved in a relatively short time (5 months),” How many
papers (PMIDs) supported the 900 pieces of evidence?
Questions about use of BEL:
Figure 4. The shorthand BEL notation is not widely recognized as a visual format and difficult to read in
general. An easy to read visualization format would make the network figures much easier to understand.
Also, what do the different edge end symbols (e.g. arrow, dot, diamond) mean?
Part C of Figure 1 mentions “BEL to openBEL conversion”. What’s the difference between BEL and
openBEL?
Other comments:
A broader review of the literature of pathway databases and crowdsourcing efforts should be included in
the introduction.
I have read this submission. I believe that I have an appropriate level of expertise to confirm that
it is of an acceptable scientific standard.
Competing Interests: No competing interests were disclosed.
Author Response 12 May 2015

Stephanie Boue, Philip Morris, Switzerland
High quality curation by trained database curators is needed in our community to convert the
literature to computable models, but it is difficult to imagine how manual curation will scale to
handle the ever-growing data generation rate in biology. Thus, the biological research community
needs to figure out how to get crowdsourcing working for everyone as a tool to improve access to
computable data. This paper does a very good job of describing how a set of COPD networks were
constructed and enhanced (they grew in size and level of detail) through an interesting three-phase
process. However, it would be useful to better describe the utility of the resulting networks and to
further analyze the crowdsourcing process itself. Addressing these points will give the work a
broader impact.
Authors’ response: We have previously published several papers introducing use cases where
the biological signal is interpreted in a meaningful manner using the causal network models 1-7 and
have added these references to support the statement in the text. The point of the reviewer is
absolutely relevant and we acknowledge that it will be of utmost importance to critically assess how
the usefulness of the networks changed through each phase of the network verification project. As
a first step, the previously published analyses can be repeated with the crowd-verified networks to
assess the impact of network verification on data interpretation. A thorough assessment of the
impact of crowd verification, requires however an extensive analysis leveraging multiple relevant
datasets and to be reported thoroughly would dissolve the intended content of this manuscript that
concentrates on the way networks were built and later on verified and refined through a
crowdsourcing approach. We will conduct such an analysis and include the reference as soon as it
will become available. We have now addressed these points in the discussion.
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will become available. We have now addressed these points in the discussion.
Utility of networks:
It is not clear what advantages the use of causal networks brings compared to more established
models in the community, such as molecular interaction networks used by many algorithms (e.g.
gene function prediction, module detection, interpretation of molecular profile data, network
biomarkers) or detailed biochemical pathway models (used by most textbooks and pathway
databases). While many results are published in terms of causal networks (e.g. A activates B), one
important issue with networks constructed by collecting these relationships is that they may be
difficult to integrate across resources since they are context specific: A may activate B in the lung,
but inhibit B in the heart and when these are integrated, a conflict arises. Many computational
analysis methods require integration of networks from multiple sources to construct the largest
available network and integrate this data with disease-specific molecular profile data (e.g. gene
expression data) to gain context (as it seems is done in the RCR approach). It would be useful for
the authors to further discuss the utility of context-specific causal networks for follow on discovery.
Authors’ response: The usage of causal networks allows all applications that other network
models would have, and in addition eases the biological interpretation of the results in a
mechanistic, cause and effect fashion. The new, sophisticated algorithms that have been
developed to analyze molecular data using the causal network models fully exploit the specific
structure of two-layer cause-and-effect network models, providing evidence that causality adds
precision on top of interaction1,2,8. However, as the reviewer points out, causality may differ across
conditions (space and time), and the usage of BEL is therefore particularly relevant, as it allows for
detailed context annotation of each piece of evidence linked to a causal edge. To fully make use of
this property, it is important that as much of the literature evidence are collected in a
knowledgebase, which will only really be doable thanks to new text mining methods assisting the
biologists with the creation of BEL evidences or via crowdsourcing efforts such as the one
described here. Because it is a very large undertaking, we have so far tried to restrict the
evidences to respiratory and cardiovascular context. It is not excluded, however, that as the crowd
and interest for the network grows, a more comprehensive annotation of the networks are
achieved, making them usable in a specific context. Furthermore, BEL is being used in both
academic and industry settings and BEL converters are being developed that can translate
information from other sources such as BioPAX and SBML to facilitate comprehensive aggregation
of networks.
I only noticed one sentence mentioning use: “By building the network model set in the BEL
language format, we have generated a model framework suitable for biomarker discovery and for
the interpretation of transcriptomic signatures found in human lung tissue.” However, this sentence
is not clear and doesn’t cite any prior literature. How does using the BEL format create models
suitable for biomarker discovery? Can’t molecular interaction or other types of networks also be
used for biomarker discovery? What type of biomarker discovery is referred to here? How are
transcriptomic signatures interpreted and analyzed?
Authors’ response: We have previously published several papers introducing use cases where
the biological signal is interpreted in a meaningful manner using the causal network models 1-7 and
have added these references to support the statement in the text. Martin et al. describes the
development of network signatures that identify mechanisms that may explain differential drug
treatment response between individuals, demonstrating that the causal two layered networks allow
analyses which go beyond what normal networks can provide, i.e. provide classification power
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analyses which go beyond what normal networks can provide, i.e. provide classification power
coupled with mechanistic detail8.
Crowdsourcing comments:
“Networks that were not enhanced with COPD-specific mechanisms from the literature or RCR
included the DNA Damage and Notch Signaling networks. Although both these networks relevant
to the development of COPD, they were not augmented beyond the original, non-diseased network
scaffolds, because no studies on the differences in signaling between non-diseased and diseased
states were available.” How do the authors know that no relevant studies were available? It seems
that many papers at least have discussed links between COPD and DNA damage or Notch
signaling (e.g. PMID: 19106307 published in 2009 “Down-regulation of the notch pathway in
human airway epithelium in association with smoking and chronic obstructive pulmonary disease.”)
Authors’ response: We reformulated the sentence. Although there may be papers that report on
the correlation between COPD and these processes like the Notch paper you mention, we are
referring to mechanistic papers that will provide causal links within the model. For example, a
paper from a NOTCH1 knockout experiment in a COPD animal model that shows a particular
protein being decreased will allow us to add the causal link of NOTCH1 activity increasing that
protein in the Notch signaling COPD model. These are the types of causal mechanistic papers we
have searched for and have not found in the context of COPD.
“In total, 12 new nodes and 28 new edges were added to the Th1-Th2 Signaling network model
during the jamboree discussions, thereby creating a comprehensive biological network of T-helper
cell activity and their interactions with other immune cells in the context of COPD.” How is
‘comprehensive’ measured? How do we know how much of the available literature was covered by
the crowdsource process? That is, what is the sensitivity of the crowdsourcing process?
Authors’ response: As to avoid any confusion, and because the sensitivity of crowdsourcing is
not easily measurable (as it would require to assess all possible literature), we reformulated to
“more comprehensive”.
How many contributors were involved in enhancing each network in phase 2? Where were they
from e.g. academia, industry? What incentivized them to contribute – for instance, were they
COPD researchers? For the sake of research into crowdsourcing in biology, it would be very useful
to provide additional analysis of the contributor community. We need to learn more about what
works and what doesn’t in crowdsourcing initiatives so future generations of these approaches can
be improved.
Authors’ response: A specific publication addresses the statistics related to participation9.
Clearly, the most difficult part of such a crowdsourcing project is to get the right incentives for
people to participate. We acknowledge that showing the usefulness of the networks and their
refinements should allow for a bigger buy-in from the scientific community, and likely more
participation.
The authors state “With nearly 900 new pieces of evidence added by the challenge crowd, a
significant overall enhancement of the networks was achieved in a relatively short time (5 months),”
How many papers (PMIDs) supported the 900 pieces of evidence?
Authors’ response: 479 unique PMIDs supported the 886 new pieces of evidence. We have
included this detail in the text.
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included this detail in the text.
Questions about use of BEL:
Figure 4. The shorthand BEL notation is not widely recognized as a visual format and difficult to
read in general. An easy to read visualization format would make the network figures much easier
to understand. Also, what do the different edge end symbols (e.g. arrow, dot, diamond) mean?
Authors’ response: We have added a legend to the figure. Please note that the bionet website
also has a legend for the network visualization part.
Part C of Figure 1 mentions “BEL to openBEL conversion”. What’s the difference between BEL and
openBEL?
Authors’ response: BEL was a proprietary language developed by Selventa. In the interest of the
growing community of researchers using BEL, an openBEL language derived from BEL has been
developed and released as open source http://www.openbel.org/. One of the main differences
between the two is that in the openBEL, the namespace (i.e. databases in which the biological
entity is defined) is clearly stated, allowing for a better standardization of used ontologies and
databases. We have added this specification in the figure legend.
Other comments:
A broader review of the literature of pathway databases and crowdsourcing efforts should be
included in the introduction.
Authors’ response: We have discussed the comparison of our network models with other
resources in other publications2,9,10. We have added this statement with appropriate references in
the discussion for readers, who wish to find more background information about the network
models and see how they compared with other approaches to interpret data.
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Winston Hide
Department of Biostatistics, Harvard School of Public Health, Boston, MA, USA
This work uses a hybrid approach network modelling approach to incorporate predictive methodology
with empirical knowledge and crowd sourcing for models of COPD pathogenesis. It is a good idea,
thoroughly implemented and has produced a potentially useful set of pathways. The value of the resulting
pathways is not clear as they do not have community validation, only community design.
The manuscript is exhaustive in its descriptions and the process of developing the models is clear.
The work represents the first phase of understanding for knowledge driven development of
network models of COPD - the process of building the models is well described and the actual outcomes
of the interactions with community are informative. The question of the actual true value of the models in
terms of their accuracy, adoption and accessibility is not yet convincingly addressed. That may be
expected as the purpose of this work appears to be a description of the first part of the process of
developing knowledge based models for a disease. The models as presented appear unvalidated
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developing knowledge based models for a disease. The models as presented appear unvalidated
and without a description of the framework for assessing the value and actioning of the networks, it is not
clear how their uptake by the community will be assured.
This is a unique effort but the manuscript should make more reference to
existing pathway based community annotation efforts e.g.: wikipathways and/or open science initiatives
such as those promoted by community interaction leaders such as Andrew Su. It should show how the
value of this approach differs to existing efforts.
In terms of access to expertise, it is not clear how an uninvited scientist would contribute to an existing
pathway model - except through the open but time-limited crowdsourcing venue.
Straightforward validation of the models network is not tested in terms of their consistency or
cross-valdiation within COPD high dimensional assays - where it should be possible to see evidence of
enrichment for co-expression etc.
Contextual nature of networks is mentioned and attempts are made to address contextual pathway
structures, but the context is not tested.
As a suggestion the authors should consider community validation
Pathway accessibility and distribution is described but it is not clear as to how these models are available
in any format except web browsing. For the models to be tested by the community, value would come
from making them openly available as downloadable instances in several of the most popular formats.
Feedback on their accuracy could then be encouraged.
I have read this submission. I believe that I have an appropriate level of expertise to confirm that
it is of an acceptable scientific standard.
Competing Interests: I was an invitee to one of the Improver conferences to present a talk but did not
contribute to the manuscript or models. I know S. Boue as a previous collaborator and colleague on a
publication "ASTD: The Alternative Splicing and Transcript Diversity database.,” vol. 93, no. 3, pp.
213–220, Mar. 2009."
Author Response 12 May 2015

Stephanie Boue, Philip Morris, Switzerland
This work uses a hybrid approach network modelling approach to incorporate predictive
methodology with empirical knowledge and crowd sourcing for models of COPD pathogenesis. It is
a good idea, thoroughly implemented and has produced a potentially useful set of pathways. The
value of the resulting pathways is not clear as they do not have community validation, only
community design. The manuscript is exhaustive in its descriptions and the process of developing
the models is clear.
The work represents the first phase of understanding for knowledge driven development of
network models of COPD - the process of building the models is well described and the actual
outcomes of the interactions with community are informative. The question of the actual true value
of the models in terms of their accuracy, adoption and accessibility is not yet
convincingly addressed. That may be expected as the purpose of this work appears to be
a description of the first part of the process of developing knowledge based models for a disease.
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a description of the first part of the process of developing knowledge based models for a disease.
The models as presented appear unvalidated and without a description of the framework for
assessing the value and actioning of the networks, it is not clear how their uptake by the
community will be assured.
Authors’ response: The point of the reviewer is absolutely relevant and we acknowledge that it
will be of utmost importance to critically assess how the usefulness of the networks changed
through each phase of the project. Whenever possible, orthogonal data sets were used to validate
the network model during the building process. In the paper Systematic verification of upstream
regulators of a computable cellular proliferation network model on non-diseased lung cells using a
dedicated dataset, we have done just that by using a specifically designed, independent lung cell
proliferation dataset to verify the correctness of the cell cycle network model 1. The validation of all
available networks requires an extensive analysis leveraging multiple relevant datasets and to be
reported thoroughly would dissolve the intended content of this manuscript that concentrates on
the way networks were built and later on verified and refined through a crowdsourcing approach.
We will conduct such an analysis and make sure to reference it here as soon as it will be available.
This is a unique effort but the manuscript should make more reference to
existing pathway based community annotation efforts e.g.: wikipathways and/or open science
initiatives such as those promoted by community interaction leaders such as Andrew Su. It should
show how the value of this approach differs to existing efforts.
Authors’ response: We have discussed the comparison of our network models with other
resources in other articles2,3 and in a book chapter4. We have added this statement in the
discussion for readers who wish to find more background information about the network models
and see how they compared with other approaches to interpret data.
In terms of access to expertise, it is not clear how an uninvited scientist would contribute to an
existing pathway model - except through the open but time-limited crowdsourcing venue.
Straightforward validation of the models network is not tested in terms of their consistency or
cross-valdiation within COPD high dimensional assays - where it should be possible to see
evidence of enrichment for co-expression etc.
Contextual nature of networks is mentioned and attempts are made to address contextual pathway
structures, but the context is not tested.
As a suggestion the authors should consider community validation
Pathway accessibility and distribution is described but it is not clear as to how these models are
available in any format except web browsing. For the models to be tested by the community, value
would come from making them openly available as downloadable instances in several of the most
popular formats. Feedback on their accuracy could then be encouraged.
Authors’ response: The networks can be browsed on the bionet.sbvimprover.com website,
including latest votes and modification. More stable versions are stored in the causalbionet.com
database2.
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